Mainstream

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds

Rhythm Pharma gains as mid-stage trial for rare form of obesity succeeds

Post ContentrytmRead More

You might also be interested in reading TELUS International GAAP EPS of -$0.20 misses by $0.06, revenue of $691M beats by $18.02M.

July 9, 2025
In Mainstream